Abstract: The present invention relates to a pharmaceutical composition containing ?-lapachone as an active ingredient for prevention or treatment of cholestatic liver disease, and can provide agents for effectively preventing and treating cholestatic liver disease.

Abstract: A liquid crystal display device containing a liquid crystal panel that includes a first substrate, a second substrate, and first and second polarizers at respective outer surfaces of the first and second substrates; and a backlight unit under the liquid crystal panel that includes a light source, wherein the light source includes a first luminous body having a first peak wavelength, a second luminous body having a second peak wavelength greater than the first peak wavelength, and a third luminous body having a third peak wavelength greater than the second peak wavelength, and wherein the first polarizer contains a light absorption layer having an absorption peak between the second peak wavelength and the third peak wavelength.

Abstract: A liquid crystal display device containing a liquid crystal panel that includes a first substrate, a second substrate, and first and second polarizers at respective outer surfaces of the first and second substrates; and a backlight unit under the liquid crystal panel that includes a light source, wherein the light source includes a first luminous body having a first peak wavelength, a second luminous body having a second peak wavelength greater than the first peak wavelength, and a third luminous body having a third peak wavelength greater than the second peak wavelength, and wherein the first polarizer contains a light absorption layer having an absorption peak between the second peak wavelength and the third peak wavelength.